Patriot Financial Group Insurance Agency LLC Has $671,000 Holdings in GSK plc (NYSE:GSK)

Patriot Financial Group Insurance Agency LLC boosted its stake in GSK plc (NYSE:GSK) by 5.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,408 shares of the pharmaceutical company’s stock after buying an additional 903 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in GSK were worth $671,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. 1832 Asset Management L.P. grew its holdings in shares of GSK by 9.1% in the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after purchasing an additional 257 shares during the last quarter. Boltwood Capital Management grew its stake in GSK by 2.5% during the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 270 shares during the last quarter. J.W. Cole Advisors Inc. increased its holdings in shares of GSK by 4.7% during the first quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock worth $261,000 after buying an additional 271 shares in the last quarter. First Affirmative Financial Network raised its stake in shares of GSK by 4.7% in the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after acquiring an additional 283 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in GSK by 9.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after acquiring an additional 303 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Price Performance

GSK stock opened at $37.90 on Tuesday. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $78.54 billion, a P/E ratio of 13.73, a PEG ratio of 1.23 and a beta of 0.65. The business has a 50-day moving average of $41.05 and a 200-day moving average of $41.13. GSK plc has a 1 year low of $33.67 and a 1 year high of $45.92.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. On average, equities analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were paid a dividend of $0.3843 per share. This represents a $1.54 annualized dividend and a yield of 4.06%. The ex-dividend date was Friday, August 16th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Jefferies Financial Group boosted their price objective on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Argus raised shares of GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Barclays raised shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK presently has an average rating of “Buy” and an average price target of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.